CD4 and neoplasm: A trial in rGB patients tested this hypothesis and showed an increase in the mOS, a specific peripheral immune response to the peptides bound to HSPPC-96, a focal cellular infiltrate of CD4+ and CD8+ and, in addition, brain biopsies were consistent with specific immune responses at the tumor site [678,679].